Description
The HP-MA4 monoclonal antibody specifically recognizes several Killer Cell Immunoglobulin-like Receptors (KIRs) which are also known as CD158 molecules. HP-MA4 recognizes Killer cell immunoglobulin-like receptor 2DL1 (encoded by KIR2DL1; aka, CD158a and NKAT-1), Killer cell immunoglobulin-like receptor 2DS1 (KIR2DS1; CD158h), Killer cell immunoglobulin-like receptor 2DS3 (KIR2DS3; NKAT-7), and Killer cell immunoglobulin-like receptor 2DS5 (KIR2DS5; CD158g, NKAT-9) which are collectively known as KIR2DL1/S1/S3/S5 (CD158). These type I transmembrane glycoproteins are encoded by polymorphic genes and have 2 extracellular Ig-like domains (KIR2D, domains D1 and D2) followed by a transmembrane region and either long (L) or short (S) cytoplasmic domains. Various CD158 molecules are differentially expressed by CD56dim natural killer (NK) cells and some T cells and can regulate their cytotoxic effector functions. Although different KIR gene content varies amongst haplotypes for individuals, certain "framework" genes including KIR3DL3, KIR3DP1, KIR3DL4, and KIR3DL2, are found in all haplotypes. KIR2DL1 has a long cytoplasmic domain with two tyrosine-based inhibitory motifs (ITIM) that enables inhibitory signal transduction by ligand-bound KIR2DL1 leading to reduced cytotoxic effector cell activity. KIR2DS1, KIR2DS3, KIR2DS5 (KIR2DS1/S3/S5) proteins each have a short cytoplasmic tail with a positively charged amino acid in their transmembrane region which allows association with the DAP12 transmembrane protein. DAP12 acts as an activating signal transduction element through its immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain leading to upregulated cytotoxic effector cell function. Some MHC class I molecules can serve as ligands for CD158 molecules, with HLA-C ligands reported for KIR2DL1, KIR2DS1, and KIR2DS5.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
Specifications

General

SourceHuman FGFR4, amino acids (Leu22-Asp369) (Accession# BC011847), with a linker sequence (GSSR) and a C-terminal human IgG1 (Pro100 - Lys330) was expressed in 293E cells.
Molecular MassThe 583 amino acid recombinant protein has a predicted molecular mass of approximately 64.8 kD. The protein migrates approximately at 95-100 kD in DTT-reducing conditions and at 160-170 kD in non-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is Leu.
Purity>95%, as determined by Coomassie stained SDS-PAGE.
Formulation0.22 µm filtered protein solution is in PBS, pH 7.2.
Endotoxin LevelLess than 0.01 ng per µg cytokine as determined by the LAL method.
Concentration10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & HandlingUnopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
ActivityED50 = 5 - 10 ng/ml, corresponding to a specific activity of 1 - 2 x 105 units/mg, as determined by a dose-dependent inhibition of FGF acidic-dependent NIH3T3 cell proliferation. The concentration of FGF acidic (Cat. No. 599202) used in the assay was 0.5 ng/ml. The inhibition of proliferation was measured by the colorimetric MTS assay.
ApplicationBioassay
Application NotesBioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Product CitationsLee H, et al. 2024. Nat Commun. 1003:15. PubMed
StructureGrowth factor receptor, in a chimeric format.
DistributionFGFR4 can be detected in human adult tissues including the liver, sublingual gland ducts, kidney, ureter, and in the media of some arterioles and veins in most tissues.
FunctionFGFR4 is a conserved tyrosine kinase receptor that regulates cell proliferation, differentiation, migration, and cellular metabolism.
Ligand/ReceptorFGF-1, FGF-8, FGF-17, FGF-18, FGF-19, FGF-21, and FGF-23. ßKlotho protein is a co-receptor of FGFR4 for FGF-19 binding.
Cell TypeEmbryonic Stem Cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, Neural Stem Cells
Biology AreaCell Biology, Neuroscience, Stem Cells, Synaptic Biology
Molecular FamilyCytokine/Chemokine Receptors, Soluble Receptors
Antigen References1. Zhang X, et al. 2006. J. Biol. Chem. 281:15694. 2. Beenken A and Mohammadi M. 2009. Nat. Rev. Drug Discov. 8:235. 3. Wang J, et al. 2008. Neoplasia. 8:847. 4. Thussbas C, et al. 2006. J. Clin. Oncol. 24:3747. 5. Lin BC, et al. 2007. J. Biol. Chem. 282:27277. 6. Gauglhofer C, et al. 2014. Carci. 35:2331. 7. Wang J, et al. 2004. Clin. Cancer Res. 10:6169. 8. Sugiyama N, et al. 2010. Cancer Res. 70:7851. 9. Hughes SE. 1997. J. Histochem. Cytochem. 45:1005.
Gene ID2264
UniProtView information about FGFR4 on UniProt.org
Regulatory StatusRUO
Other NamesCD334, Fibroblast growth factor receptor 4